THE EFFECT OF BROMOCRIPTINE ON INSULIN SECRETION AND GLUCOSE TOLERANCE IN PATIENTS WITH ACROMEGALY
THE EFFECT OF BROMOCRIPTINE ON INSULIN SECRETION AND GLUCOSE TOLERANCE IN PATIENTS WITH ACROMEGALY
复制标题
溴隐亭对肢端肥大症患者胰岛素分泌和葡萄糖耐量的影响
DOI：
10.1111/j.1365-2265.1981.tb00690.x
复制
发表时间：
1981
影响因子：
3.2
通讯作者：
J. Baird
中科院分区：
文献类型：
--
作者：
C. Feek;J. S. Bevan;S. Taylor;N. Brown;J. Baird
在50 g口服葡萄糖耐量试验（OGTT）期间，12例肢端肥大症患者口服溴隐亭5 mg，每6小时一次，平均持续12个月（范围3-27），显著降低了全血葡萄糖、血浆胰岛素和血浆生长激素（GH）浓度。在此治疗期后，停用溴隐亭48小时，导致重复OGTT期间全血葡萄糖、血浆胰岛素和血浆GH浓度显著升高。可以得出结论，溴隐亭治疗通过抑制GH分泌和GH介导的胰岛素拮抗作用改善肢端肥大症的葡萄糖耐量。
The oral administration of bromocriptine 5 mg 6‐hourly to twelve patients with acromegaly for a mean period of 12 (range 3–27) months significantly reduced whole blood glucose, plasma insulin and plasma growth hormone (GH) concentrations during a 50 g oral glucose tolerance test (OGTT). After this period of treatment, bromocriptine was withdrawn for 48 h resulting in a significant rise in whole blood glucose, plasma insulin and plasma GH concentrations during a repeat OGTT. It is concluded that bromocriptine therapy improves glucose tolerance in acromegaly by suppressing GH secretion and consequently GH‐mediated antagonism of insulin.